Is hypoglycaemia a modifiable patient risk in type 2 diabetes: A pooled analysis of insulin glargine 300 U/mL (Gla-300) vs 100U/mL (Gla-100) trials?

被引：0
|
作者：
Zhang, Q. [1 ]
Rosenstock, J. [2 ]
Gerrits, C. [3 ]
Liao, L. [3 ]
Chew, P. [3 ]
机构：
[1] Rutgers State Univ, Piscataway, NJ USA
[2] Dallas Diabet & Endocrine Ctr, Dallas, TX USA
[3] Sanofi, Bridgewater, MA USA
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
974
引用
收藏
页码：S472 / S472
页数：1
相关论文
共 50 条
  • [1] Is Hypoglycemia a Modifiable Patient Risk in Type 2 Diabetes? A Pooled Analysis of Insulin Glargine 300U/mL (Gla-300) vs. 100U/mL (Gla-100) Trials
    Rosenstock, Julio
    Zhang, Quanwu
    Gerrits, Charles
    Liao, Laura
    Chew, Paul
    [J]. DIABETES, 2015, 64 : A110 - A110
  • [2] New insulin glargine 300U/ml (Gla-300): glycaemic control and hypoglycaemia in insulin-naive people with Type 2 diabetes compared with glargine 100U/ml (Gla-100)
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Sestakauskas, K.
    Goyeau, H.
    Home, P. D.
    [J]. DIABETIC MEDICINE, 2015, 32 : 78 - 78
  • [3] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
    Yang, K. -H.
    Tseng, C. -T.
    Chen, L. -C.
    Chen, P. -C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
  • [4] INSULIN GLARGINE 300 U/ML (GLA-300) VS 100 U/ML (GLA-100) IN OLDER PEOPLE WITH T2DM: RESULTS FROM A RANDOMIZED TRIAL
    Ritzel, R.
    Espinasse, M.
    Muehlen-Bartmer, I.
    Zhang, N.
    Munshi, M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A135 - A136
  • [5] SWITCHING TO INSULIN GLARGINE 300 U/ML (GLA-300): BENEFITS VS GLA-100 BY DURATION OF PRIOR BASAL INSULIN THERAPY
    Bonadonna, R. C.
    Renard, E.
    Cheng, A.
    Fritsche, A.
    Glezer, S.
    Cali, A.
    Grisoni, M. L.
    Umpierrez, G.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A31 - A31
  • [6] Insulin Glargine 300 U/mL (Gla-300) vs 100 U/mL (Gla-100) in older people with T2Dm: Results from a randomized trial
    Ritzel, Robert
    Vonbank, Alexander
    Espinasse, Melanie
    Muehlen-Bartmer, Ingrid
    Zhang, Nue
    Munshi, Medha
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 369 - 369
  • [7] Reported Pregnancy Outcomes with Insulin Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) : Post-Marketing Survey of Pharmacovigilance Data
    Westerbacka, Jukka
    Bassole, Caroline
    Duverne, Marielle
    Doder, Zoran
    Schoepper, Heike
    [J]. DIABETES, 2022, 71
  • [8] INSULIN GLARGINE 300 U/ML (GLA-300) VS 100 U/ML (GLA-100) IN PEOPLE ≥75 YEARS OLD WITH T2DM: SECONDARY ANALYSIS OF THE SENIOR STUDY
    Harris, S.
    Ritzel, R.
    Roussel, R.
    Baron, H.
    Florez, H.
    Espinasse, M.
    Muehlen-Bartmer, I.
    Zhang, N.
    Munshi, M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A136 - A136
  • [9] A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen
    Bolli, Geremia B.
    Wysham, Carol
    Fisher, Miles
    Chevalier, Soazig
    Cali, Anna M. G.
    Leroy, Bruno
    Riddle, Matthew C.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (02): : 402 - 407
  • [10] ONE-YEAR COST-UTILITY EVALUATION OF INSULIN GLARGINE 300U/ML (GLA-300) VERSUS INSULIN GLARGINE 100U/ML (GLA-100) IN PATIENTS WITH TYPE 2 DIABETES (T2DM) IN THAILAND
    Thongsri, W.
    Rattanawongsawad, S.
    Fournier, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S39 - S39
12345